Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

  • 1, 13Email author,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9,
  • 10,
  • 11,
  • 6 and
  • 12
BMC Cancer201616:518

https://doi.org/10.1186/s12885-016-2559-8

  • Received: 13 July 2016
  • Accepted: 13 July 2016
  • Published:

The original article was published in BMC Cancer 2016 16:412

Erratum

After publication of the original article [1], an error was noticed within the title: acronym “REBECCA” was erroneously written as “REBACCA”. The original article has now been updated with the correct title which can also be found above. The publisher would like to apologise for this error and for any inconvenience this may have caused.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Medical Oncology, Centre Oscar Lambret and Catholic University, Lille, France
(2)
Medical Oncology, Centre Léon Bérard, Lyon, France
(3)
Medical Oncology, Paul Brousse University Hospital, Villejuif, France
(4)
Medical Oncology, Gustave Roussy, Villejuif, France
(5)
Gastroenterology, University Hospital, Poitiers, France
(6)
Methodology and Biostatistics, Centre Oscar Lambret, Lille, France
(7)
Medical Oncology, Clinique Sainte Anne, Strasbourg, France
(8)
Medical Oncology, Hopital Privé des Côtes d’Armor, Plérin, France
(9)
Radiation and Medical Oncology, Institut Sainte-Catherine, Avignon, France
(10)
Clinical Research Unit, Centre Oscar Lambret, Lille, France
(11)
Gastroenterology, University Hospital, Saint Etienne, France
(12)
Medical Oncology, Saint Antoine Hospital, and University Pierre et Marie Curie (UMPC), Paris VI, Paris, France
(13)
Department of Medical Oncology, Centre Oscar Lambret, 3, rue F Combemale, 59000 Lille, France

References

  1. Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. 2016;16:412. doi:10.1186/s12885-016-2440-9.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement